Literature DB >> 21699828

Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival.

David L Hayes1, John P Boehmer, John D Day, F R Gilliam, Paul A Heidenreich, Milan Seth, Paul W Jones, Leslie A Saxon.   

Abstract

BACKGROUND: With the advent of cardiac resynchronization therapy, it was unclear what percentage of biventricular pacing would be required to obtain maximal symptomatic and mortality benefit from the therapy. The optimal percentage of biventricular pacing and the association between the amount of continuous pacing and survival is unknown.
OBJECTIVE: The purpose of this study was to assess the optimal percentage of biventricular pacing and any association with survival in a large cohort of networked patients.
METHODS: A large cohort of 36,935 patients followed up in a remote-monitoring network, the LATITUDE Patient Management system (Boston Scientific Corp., Natick, Massachusetts), was assessed to determine the association between the percentage of biventricular pacing and mortality.
RESULTS: The greatest magnitude of reduction in mortality was observed with a biventricular pacing achieved in excess of 98% of all ventricular beats. Atrial fibrillation and native atrial ventricular condition can limit a high degree of biventricular pacing. Incremental increases in mortality benefit are observed with an increasing percentage of biventricular pacing.
CONCLUSION: Every effort should be made to reduce native atrioventricular conduction with cardiac resynchronization therapy systems in an attempt to achieve biventricular pacing as close to 100% as possible.
Copyright © 2011 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21699828     DOI: 10.1016/j.hrthm.2011.04.015

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  70 in total

Review 1.  The application of Big Data in medicine: current implications and future directions.

Authors:  Christopher Austin; Fred Kusumoto
Journal:  J Interv Card Electrophysiol       Date:  2016-01-27       Impact factor: 1.900

2.  Periprocedural management of cardiac resynchronization therapy.

Authors:  John Rickard; Niraj Varma
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-04

3.  Nonpharmacological Treatment of Atrial Fibrillation: What Is the Role of Device Therapy?

Authors:  Lucie Riedlbauchová; Václav Durdil; Jakub Honěk; Josef Veselka
Journal:  Int J Angiol       Date:  2020-04-28

Review 4.  Novel Pacing Strategies for Heart Failure Management.

Authors:  Jordan S Leyton-Mange; Theofanie Mela
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-08

5.  ICD lead type and RV lead position in CRT-D recipients.

Authors:  Alexander P Benz; Mate Vamos; Julia W Erath; Peter Bogyi; Gabor Z Duray; Stefan H Hohnloser
Journal:  Clin Res Cardiol       Date:  2018-05-24       Impact factor: 5.460

6.  Cardiac resynchronization therapy and outcomes in patients with left ventricular assist devices: a systematic review and meta-analysis.

Authors:  Dinesh Chandra Voruganti; Alexandros Briasoulis; Mohsan Chaudhry; Paulino Alvarez; Vlad Cotarlan; Jay K Bhama; Michael Giudici
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

Review 7.  Non-response to Cardiac Resynchronization Therapy.

Authors:  Syed Yaseen Naqvi; Anas Jawaid; Ilan Goldenberg; Valentina Kutyifa
Journal:  Curr Heart Fail Rep       Date:  2018-10

Review 8.  Atrial fibrillation and conduction system disease: the roles of catheter ablation and permanent pacing.

Authors:  Anand Thiyagarajah; Dennis H Lau; Prashanthan Sanders
Journal:  J Interv Card Electrophysiol       Date:  2018-08-03       Impact factor: 1.900

Review 9.  Devices in the management of advanced, chronic heart failure.

Authors:  William T Abraham; Sakima A Smith
Journal:  Nat Rev Cardiol       Date:  2012-12-11       Impact factor: 32.419

10.  Expanding indications for resynchronization therapy.

Authors:  Christophe Leclercq; Nathalie Behar; Philippe Mabo; Jean-Claude Daubert
Journal:  Curr Cardiol Rep       Date:  2012-10       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.